|
1
|
Vizcaino AP, Moreno V, Bosch FX, et al:
International trends in incidence of cervical cancer: II.
Squamous-cell carcinoma. Int J Cancer. 86:429–435. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koutsky L: Epidemiology of genital human
papillomavirus infection. Am J Med. 102:3–8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moore DH, Blessing JA, McQuellon RP, et
al: Phase III study of cisplatin with or without paclitaxel in
stage IVB, recurrent, or persistent squamous cell carcinoma of the
cervix: a gynecologic oncology group study. J Clin Oncol.
22:3113–3119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer-a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Simon JA: Transcription. Sweet silencing.
Science. 325:45–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valk-Lingbeek ME, Bruggeman SW and van
Lohuizen M: Stem cells and cancer; the polycomb connection. Cell.
118:409–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei Y, Chen YH, Li LY, et al:
CDK1-dependent phosphorylation of EZH2 suppresses methylation of
H3K27 and promotes osteogenic differentiation of human mesenchymal
stem cells. Nat Cell Biol. 13:87–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen S, Bohrer LR, Rai AN, et al:
Cyclin-dependent kinases regulate epigenetic gene silencing through
phosphorylation of EZH2. Nat Cell Biol. 12:1108–1114. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Viré E, Brenner C, Deplus R, et al: The
Polycomb group protein EZH2 directly controls DNA methylation.
Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gieni RS and Hendzel MJ: Polycomb group
protein gene silencing, non-coding RNA, stem cells, and cancer.
Biochem Cell Biol. 87:711–746. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gong Y, Huo L, Liu P, et al: Polycomb
group protein EZH2 is frequently expressed in inflammatory breast
cancer and is predictive of worse clinical outcome. Cancer.
117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao W, Feng Z, Cui Z, et al: Up-regulation
of enhancer of zeste homolog 2 is associated positively with cyclin
D1 overexpression and poor clinical outcome in head and neck
squamous cell carcinoma. Cancer. 118:2858–2871. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao W, Younis RH, Li J, et al: EZH2
promotes malignant phenotypes and is a predictor of oral cancer
development in patients with oral leukoplakia. Cancer Prev Res
(Phila). 4:1816–1824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao W, Ribeiro Rde O, Liu D, et al: EZH2
promotes malignant behaviors via cell cycle dysregulation and its
mRNA level associates with prognosis of patient with non-small cell
lung cancer. PLoS One. 7:e52984–2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kikuchi J, Kinoshita I, Shimizu Y, et al:
Distinctive expression of the polycomb group proteins Bmi1 polycomb
ring finger oncogene and enhancer of zeste homolog 2 in nonsmall
cell lung cancers and their clinical and clinicopathologic
significance. Cancer. 116:3015–3024. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huqun, Ishikawa R, Zhang J, et al:
Enhancer of zeste homolog 2 is a novel prognostic biomarker in
nonsmall cell lung cancer. Cancer. 118:1599–1606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He LR, Liu MZ, Li BK, et al: High
expression of EZH2 is associated with tumor aggressiveness and poor
prognosis in patients with esophageal squamous cell carcinoma
treated with definitive chemoradiotherapy. Int J Cancer.
127:138–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hinz S, Weikert S, Magheli A, et al:
Expression profile of the polycomb group protein enhancer of Zeste
homologue 2 and its prognostic relevance in renal cell carcinoma. J
Urol. 182:2920–2925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ntziachristos P, Tsirigos A, Van
Vlierberghe P, et al: Genetic inactivation of the polycomb
repressive complex 2 in T cell acute lymphoblastic leukemia. Nat
Med. 18:298–301. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou T, Liang D, Xu L, et al: Atypical
chemokine receptors predict lymph node metastasis and prognosis in
patients with cervical squamous cell cancer. Gynecol Oncol.
130:181–187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shibata D: Mutation and epigenetic
molecular clocks in cancer. Carcinogenesis. 32:123–128. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Valk-Lingbeek ME, Bruggeman SW and van
Lohuizen M: Stem cells and cancer; the polycomb connection. Cell.
118:409–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Roh JW, Bandyopadhyay S, et al:
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal
adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol
Oncol. 128:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Bitler BG, Vathipadiekal V, et al:
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer
identified by genome-wide approaches. Cancer Prev Res (Phila).
5:484–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen SQ, Zhang HM, Li JB, et al: Analyzing
simultaneous positive expression of EZH2 and P53 protein to improve
predictive value in cervical squamous cell carcinoma. Int J Gynecol
Cancer. 24:1653–1658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang J, Zhang M and Li Q: Enhancer of
zeste homolog 2 expression is associated with tumor cell
proliferation and invasion in cervical cancer. Am J Med Sci.
342:198–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Breuer RH, Snijders PJ, Smit EF, et al:
Increased expression of the EZH2 polycomb group gene in
BMI-1-positive neoplastic cells during bronchial carcinogenesis.
Neoplasia. 6:736–743. 2004. View Article : Google Scholar : PubMed/NCBI
|
